Enhancer Malfunction in Cancer
joint with Noncoding RNAs in Health and Disease
Organizer(s): Ali Shilatifard and Dale DorsettDate: February 21 - 24, 2016
Location: Santa Fe Community Convention Center, Santa Fe, NM, USA
Why point mutations in a general transcription factor are associated with specific forms of human malignancies has been a major question in cancer biology. Enhancers are DNA regulatory elements that can be transcribed and are key regulators of tissue-specific gene expression in development; their malfunction through point mutations in either regulatory elements or factors modulating enhancer-promoter communication could result in development problems. Indeed, recent genome-wide studies in the cataloging of somatic mutations in cancer have identified mutations in intergenic sequences encoding regulatory elements and in specific transcription factors that function in enhancer-promoter communication. This Keystone Symposia meeting will review recent reports in this regard and discuss the concept of enhancer malfunction in the misregulation of gene expression in development and in disease pathogenesis.
Scholarship Deadline: October 20 2015
Discounted Abstract Deadline: October 20 2015
Abstract Deadline: November 18 2015
Discounted Registration Deadline: December 18 2015
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
EMBO Young Investigator Programme
We gratefully acknowledge the generous grant for this conference provided by:National Cancer Institute (NCI)
Grant No. 1R13CA200208-01
Funding for this conference was made possible (in part) by 1R13CA200208-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.